Wellington Management Group LLP Acquires 100,304 Shares of Zymeworks Inc. (NYSE:ZYME)

Wellington Management Group LLP boosted its position in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 177.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 156,682 shares of the company's stock after acquiring an additional 100,304 shares during the period. Wellington Management Group LLP owned about 0.22% of Zymeworks worth $993,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZYME. Swiss National Bank boosted its position in shares of Zymeworks by 45.6% in the 1st quarter. Swiss National Bank now owns 118,500 shares of the company's stock worth $776,000 after buying an additional 37,100 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Zymeworks by 804.9% in the 1st quarter. JPMorgan Chase & Co. now owns 686,784 shares of the company's stock worth $4,498,000 after buying an additional 610,892 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Zymeworks by 12.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 71,967 shares of the company's stock valued at $471,000 after purchasing an additional 7,868 shares in the last quarter. Bank of Montreal Can grew its stake in shares of Zymeworks by 19.8% in the 1st quarter. Bank of Montreal Can now owns 24,872 shares of the company's stock worth $167,000 after purchasing an additional 4,103 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Zymeworks by 20.0% in the 1st quarter. BlackRock Inc. now owns 973,451 shares of the company's stock worth $6,377,000 after purchasing an additional 162,353 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Insider Transactions at Zymeworks

In other Zymeworks news, insider Paul Andrew Moore sold 7,460 shares of the business's stock in a transaction on Friday, January 5th. The shares were sold at an average price of $10.65, for a total transaction of $79,449.00. Following the completion of the transaction, the insider now owns 9,706 shares of the company's stock, valued at approximately $103,368.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Paul Andrew Moore sold 7,460 shares of the business's stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $10.65, for a total transaction of $79,449.00. Following the transaction, the insider now directly owns 9,706 shares in the company, valued at $103,368.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kenneth Galbraith sold 18,198 shares of the firm's stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $10.65, for a total value of $193,808.70. Following the completion of the sale, the chief executive officer now owns 29,468 shares of the company's stock, valued at approximately $313,834.20. The disclosure for this sale can be found here. Insiders sold 39,697 shares of company stock valued at $428,174 in the last three months. Corporate insiders own 1.22% of the company's stock.

Zymeworks Stock Up 2.1 %

Zymeworks stock traded up $0.22 during mid-day trading on Friday, hitting $10.52. The company's stock had a trading volume of 468,416 shares, compared to its average volume of 677,862. Zymeworks Inc. has a twelve month low of $6.01 and a twelve month high of $13.14. The stock's fifty day moving average price is $11.22 and its two-hundred day moving average price is $9.26. The stock has a market capitalization of $742.40 million, a P/E ratio of -6.05 and a beta of 1.16.

Zymeworks (NYSE:ZYME - Get Free Report) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.19. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $18.32 million. Zymeworks had a negative net margin of 156.12% and a negative return on equity of 26.20%. Equities analysts expect that Zymeworks Inc. will post -1.04 earnings per share for the current year.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.